BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36052059)

  • 1. Identification of OTUD6B as a new biomarker for prognosis and immunotherapy by pan-cancer analysis.
    Zhao G; Song D; Wu J; Yang S; Shi S; Cui X; Ren H; Zhang B
    Front Immunol; 2022; 13():955091. PubMed ID: 36052059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-Cancer Analysis Revealed
    Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
    J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
    Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
    Front Immunol; 2021; 12():688215. PubMed ID: 34305920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Cancer and Single-Cell Analysis Reveals CENPL as a Cancer Prognosis and Immune Infiltration-Related Biomarker.
    Feng Z; Chen Y; Cai C; Tan J; Liu P; Chen Y; Shen H; Zeng S; Han Y
    Front Immunol; 2022; 13():916594. PubMed ID: 35844598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pan-cancer analysis of RNASEH1, a potential regulator of the tumor microenvironment.
    Yi C; Yang J; Zhang T; Xie S; Li W; Qin L; Chen D
    Clin Transl Oncol; 2023 Aug; 25(8):2569-2586. PubMed ID: 37022517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-cancer analysis of
    Jia B; Liu J; Hu X; Xia L; Han Y
    Ann Transl Med; 2022 Dec; 10(24):1355. PubMed ID: 36660720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-Cancer Analysis of the Oncogenic and Immunological Role of
    Ding J; Meng Y; Han Z; Luo X; Guo X; Li Y; Liu S; Zhuang K
    Front Oncol; 2022; 12():811567. PubMed ID: 35651805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRPV4 is a Prognostic Biomarker that Correlates with the Immunosuppressive Microenvironment and Chemoresistance of Anti-Cancer Drugs.
    Wang K; Feng X; Zheng L; Chai Z; Yu J; You X; Li X; Cheng X
    Front Mol Biosci; 2021; 8():690500. PubMed ID: 34262942
    [No Abstract]   [Full Text] [Related]  

  • 11. BRCA1-Associated Protein Is a Potential Prognostic Biomarker and Is Correlated With Immune Infiltration in Liver Hepatocellular Carcinoma: A Pan-Cancer Analysis.
    Ju Q; Li XM; Zhang H; Zhao YJ
    Front Mol Biosci; 2020; 7():573619. PubMed ID: 33240929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

  • 13. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
    Guo L; Li X; Liu R; Chen Y; Ren C; Du S
    Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and immunological role of SERPINH1 in pan-cancer.
    Zhong H; Wang Z; Wei X; Liu Y; Huang X; Mo X; Tang W
    Front Genet; 2022; 13():900495. PubMed ID: 36105106
    [No Abstract]   [Full Text] [Related]  

  • 15. Pan-Cancer Analysis Reveals the Multidimensional Expression and Prognostic and Immunologic Roles of
    Zhang S; Xiong H; Yang J; Yuan X
    Front Mol Biosci; 2021; 8():792154. PubMed ID: 35155565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
    Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
    Front Immunol; 2022; 13():951247. PubMed ID: 35935945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-Cancer Analysis Based on
    Zhang Y; Wang S; Han S; Feng Y
    Front Oncol; 2022; 12():844794. PubMed ID: 35359375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive pan-cancer analysis reveals NUSAP1 is a novel predictive biomarker for prognosis and immunotherapy response.
    Zheng H; Wang M; Zhang S; Hu D; Yang Q; Chen M; Zhang X; Zhang Y; Dai J; Liou YC
    Int J Biol Sci; 2023; 19(14):4689-4708. PubMed ID: 37781040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
    Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
    Front Oncol; 2022; 12():927988. PubMed ID: 35756681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.